Myo-inositol vs D-chiro-inositol

Inositol has nine stereoisomers. Two are clinically relevant:

• Myo-inositol (MI). The dominant form in most tissues, including the ovary follicular fluid. Acts as a second messenger for FSH signaling. The "ovarian quality" form.
• D-chiro-inositol (DCI). Concentrated in insulin-responsive tissues like muscle and liver. Acts as a second messenger for insulin signaling. The "metabolic" form.

Both forms exist endogenously, made from glucose via an enzyme called epimerase. Insulin resistance is associated with reduced epimerase activity in the ovary, leading to relative DCI deficiency in some tissues and excess in others — the underlying biochemistry behind the PCOS-inositol research story.

The 40:1 ratio research

Healthy plasma carries myo-inositol and D-chiro-inositol in roughly a 40:1 ratio. Early PCOS research tried higher DCI ratios (1:1, 5:1) on the assumption that DCI was the "active" insulin-signaling form. Those trials produced mixed and sometimes negative results — high DCI alone appears to worsen ovarian function (Carlomagno et al., Eur Rev Med Pharmacol Sci, 2011).

The Italian research groups (Nordio, Proietto, Bevilacqua, and others) systematically tested ratios and converged on 40:1 as the most consistently effective for combined ovarian and metabolic endpoints. That ratio — 4 grams myo-inositol plus 100 mg D-chiro-inositol per day — is now the de facto clinical standard in PCOS supplement protocols across most European OB/GYN practices and increasingly in the US.

PCOS-specific research

• Unfer et al. systematic review (Gynecol Endocrinol, 2017). Pooled 12 RCTs on myo-inositol in PCOS. Significant improvements in BMI, fasting insulin, HOMA-IR, total testosterone, free androgen index, and ovulation rate vs placebo.
• Raffone et al. (Gynecol Endocrinol, 2010). 120 PCOS patients randomized to myo-inositol (4 g/day) vs metformin (1500 mg/day) for 6 months. Both groups improved similarly on BMI, ovulation, and insulin sensitivity. Inositol arm had fewer GI side effects.
• Fruzzetti et al. (Gynecol Endocrinol, 2017). Reproduced the Raffone finding with the 40:1 combined formulation vs metformin. Comparable metabolic and ovulation outcomes.
• Cochrane review (Showell et al., 2018). Inositol in subfertile women with PCOS — found improvements in metabolic markers and ovulation, though noted heterogeneity in protocols.
• D'Anna et al. (Diabetes Care, 2013). 220 high-risk pregnant women, 2 g myo-inositol + folic acid vs folic acid alone. Reduced incidence of gestational diabetes by approximately 65%.
• Greff et al. meta-analysis (Reprod Biol Endocrinol, 2023). Confirmed body weight, BMI, and insulin marker improvements with myo-inositol across PCOS RCTs.

Honest assessment: for PCOS, this is one of the strongest non-prescription evidence bases in the supplement world. It is replicated, it is multi-center, and it has been independently confirmed in head-to-head comparisons with first-line pharmacological treatment.

How it works — insulin signaling

Insulin signaling at the cellular level requires intracellular second messengers — molecules that translate the "insulin has bound to the receptor" signal into the cell's actual metabolic response. Myo-inositol and D-chiro-inositol are converted into inositol phosphoglycans (IPGs), which act as those second messengers.

In insulin-resistant tissues (common in PCOS), defects in the conversion of MI to DCI via epimerase reduce the pool of DCI-IPG available for insulin signaling in muscle and liver, while in the ovary an opposite imbalance may form. Supplying both forms in the natural 40:1 ratio appears to bypass the epimerase bottleneck and restore signaling on both sides.

Reviewed in detail by Bevilacqua and Bizzarri (Int J Endocrinol, 2018).

Doses researchers have used

The dominant PCOS protocol is 4 g myo-inositol + 100 mg D-chiro-inositol per day, typically split into two doses (morning and evening). Pregnancy-prevention-of-gestational-diabetes research has used 2 g/day of MI plus 200 mcg folic acid. Anxiety-disorder research at much higher doses (12-18 g/day) exists but is not relevant to the weight/PCOS use case. We are describing what researchers used, not prescribing for you.

Safety — one of the cleanest profiles in this category

• Generally very well-tolerated at clinical doses. Most-cited side effect: mild GI upset (nausea, soft stools) at higher doses.
• Pregnancy safety documented at studied doses (2-4 g/day myo-inositol). D'Anna and others have used it through full pregnancies without adverse outcome signals.
• Drug interactions are minimal — inositol does not significantly affect cytochrome P450 metabolism.
• Lithium interaction caveat: bipolar patients on lithium should consult their psychiatrist, as some animal data suggests inositol could counteract one of lithium's mechanisms.
• Hypoglycemia risk when stacked with insulin or sulfonylureas — same caution that applies to all insulin-sensitizing supplements.

Quality markers when buying

• 40:1 ratio explicitly labeled. The front of the bottle should specify 4,000 mg myo-inositol + 100 mg D-chiro-inositol per serving. If both numbers aren't disclosed, buy something else.
• Powder vs capsule. 4 g/day is hard to fit in pill form (you'd need roughly 8 large capsules). Many PCOS-targeted products are powdered for in-water dosing. Either is fine; capsule formats often require larger serving sizes.
• Third-party tested. USP, NSF, ConsumerLab, or a published CoA.
• Folic acid stack. Many PCOS-focused inositol products include 200-400 mcg folic acid. Reasonable; not required.
• No proprietary blend hiding the doses. "Hormone balance complex" containing inositol plus seven herbs at undisclosed amounts is not the trial-grade product.
• Reasonable price. Quality 4:1 myo+DCI products run roughly $25-40/month. Anything dramatically cheaper deserves an identity-testing check.

Who it's for — and who should skip it

• For: women with diagnosed PCOS who want a strong-evidence supplement to discuss with their OB/GYN; women with insulin resistance and irregular cycles; women at elevated risk of gestational diabetes (under medical supervision); people who tolerated metformin poorly and are looking for an alternative to discuss with their doctor.
• Not for: bipolar patients on lithium without psychiatric sign-off; anyone on insulin or sulfonylureas without prescriber supervision; people expecting fast weight loss without dietary changes; anyone substituting it for prescribed care.

Honest pros and cons

• Pros — One of the strongest non-prescription evidence bases for PCOS; replicated across multiple research groups; head-to-head comparable to metformin in several trials; excellent safety profile including documented pregnancy use; minimal drug interactions; widely available; effects build slowly but reliably.
• Cons — Requires daily consistency over months — not a "feel it today" supplement; serving size is large (4 g/day is several capsules or a scoop of powder); product quality varies wildly with proprietary blends in the category; lithium-interaction caveat for psychiatric patients; many products under-dose the D-chiro portion.

FAQ

Related coverage

• Best Inositol Supplements for PCOS 2026 — brand-level picks
• Best Berberine Supplements 2026 — insulin-resistance adjacency
• GLP-1 Natural Alternatives — insulin signaling context
• Berberine Review — overlapping insulin-sensitivity mechanism
• Cinnamon Capsules Review — adjacent glucose evidence
• Sugar Defender Review — multi-ingredient blood-sugar blend
• Insulin Sensitivity — defined
• Khloé Kardashian — low-carb + training
• Mediterranean Diet — first-line for PCOS

Sources

• Unfer et al. — Myo-inositol effects in PCOS, systematic review, Gynecol Endocrinol 2017
• Raffone et al. — Myo-inositol vs metformin in PCOS, Gynecol Endocrinol 2010
• D'Anna et al. — Myo-inositol and gestational diabetes prevention, Diabetes Care 2013
• Bevilacqua & Bizzarri — Inositol signaling review, Int J Endocrinol 2018
• Greff et al. — Inositol and PCOS meta-analysis, Reprod Biol Endocrinol 2023
• Examine.com — Myo-inositol evidence summary
• ACOG — PCOS patient resources
• FDA — Dietary Supplements